Caribou Biosciences

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chewy

Chewy has reached the big milestone of profitability and is expanding -- without a huge investment -- internationally. Caribou is progressing with a cutting-edge gene-editing technique that could lead to major growth down the road.

2 Top Growth Stocks to Buy Right Now Without Hesitation

-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the clinic --

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Ginkgo Bioworks Holdings

Caribou's gene editing technology has delivered positive results so far in its early-stage clinical trials. Ginkgo Bioworks may help top pharma companies make better drugs.

2 Exciting Biotech Stocks to Buy With Less Than $10

Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate is an off-the-shelf cellular cancer therapy for lymphoma patients.

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Beam Therapeutics

Growth stocks have rebounded to a degree this year. Even so, developmental biotech companies have still had a rough year as a whole in 2023.

2 Magnificent Growth Stocks to Buy On the Dip

BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki brings over 20 years of experience leading human resources in the biotechnology industry. She will lead Caribou's people strategy and report to Rachel Haurwitz, PhD, president and chief executive officer.

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

Editas Medicine

Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs.

1 Gene Editing Stock to Buy Now, and 1 to Sell

CRISPR Therapeutics

Recursion Pharmaceuticals

Biotechs tend to be very risky investments. Picking businesses with good management and plenty of cash can reduce risk.

3 Clever Tricks to Find Winning Biotech Stocks

Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year.

Is Caribou Biosciences (CRBU) Stock Outpacing Its Medical Peers This Year?

-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment continues in r/r MM --

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Caribou's cell therapy programs are among the most advanced that exist. So far, they also appear to be relatively safe and quite effective.

3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond

It's cumbersome and costly to manufacture complicated cell therapies. Caribou Biosciences and CRISPR Therapeutics have a better way of doing things.

This 1 Innovation Could Make These 2 Biotechs Soar by 2030

Caribou Biosciences just released promising data on its lead cancer therapy. It also just issued a bunch of new stock, improving its cash position.

Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years

Alignment Healthcare

The market has already risen sharply this year, but Wall Street analysts think these two stocks haven't received the attention they deserve. Caribou Biosciences is a clinical-stage drugmaker developing one-size-fits-all cellular cancer therapies.

2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street

Caribou Biosciences, Inc. (CRBU) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CRBU broke through the 200-day moving average, which suggests a long-term bullish trend.

Caribou Biosciences, Inc. (CRBU) Just Overtook the 200-Day Moving Average

AT&T

Sudden and dramatic downturns in a company's share price can sometimes represent an incredible buying opportunity. Caribou Biosciences and AT&T may fall into this bucket after losing a significant chunk of their value in recent trading sessions.

2 Stocks I'm Buying on the Dip This Week

Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/refractory second-line LBCL patients, are expected in the 1st half of 2024. A $25 million equity investment from Pfizer was achieved. Dose escalation updates to be released from ongoing open-label phase 1 CaMMouflage study as it progresses; This study is using CB-011 for the treatment of patients with r/r MM.

Caribou Biosciences: Positive CB-010 Data Leads To First Half 2024 Catalyst

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 19,230,769 shares of its common stock at a public offering price of $6.50 per share. All of the common stock to be sold in the offering will be offered by Caribou. The gross proceeds to Caribou from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125 million, excluding any exercise of the underwriters' option. Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,884,615 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome editing, said it would grant the underwriters a 30-day option to buy up to an extra $15 million in shares at the public offering price.

Caribou Biosciences offers more stock, and shares fall

Caribou Biosciences Inc said on Thursday its experimental CAR T-cell therapy helped clear all signs or decrease tumor size in 94% of patients being treated for a type of cancer in the lymph nodes in a small, early-stage trial.

Caribou's cell therapy shows promise in early-stage cancer study

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced an underwritten public offering of $100 million of shares of its common stock. Caribou intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the proposed offering will be offered by Caribou. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.

Caribou Biosciences Announces Proposed Public Offering of Common Stock

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is the longest CR maintained to date --

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

Gene editing holds the potential to disrupt the standard of care for scores of devastating human ailments. Caribou Biosciences and CRISPR Therapeutics are two names at the forefront of this emerging field.

2 Magnificient Growth Stocks to Buy in July

Here is how Caribou Biosciences, Inc. (CRBU) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.

Is Caribou Biosciences (CRBU) Outperforming Other Medical Stocks This Year?

The mean of analysts' price targets for Caribou Biosciences, Inc. (CRBU) points to a 316.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for Caribou Biosciences Stock (CRBU)